Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

• Status: Completed
• Trial end date: 2015-08-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JW Pharmaceutical

Criteria

Inclusion Criteria:

• Diagnosed with gout

Exclusion Criteria:

• Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)